Scott R Silva1, Brendan Martin2, Mehee Choi3, Bahman Emami3, Newton J Hurst4. 1. Department of Radiation Oncology, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky. 2. Department of Biostatistics, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois. 3. Department of Radiation Oncology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois. 4. Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan.
Abstract
BACKGROUND: We performed an analysis of the National Cancer Database (NCDB) to evaluate overall survival (OS) in patients with base of tongue (BOT) cancer treated with external beam radiation therapy (EBRT) combined with brachytherapy (BT). METHODS: The tongue NCDB Participant User File was used to obtain demographic and clinical patient data. The Kaplan-Meier method was used to determine OS. Significance was determined using univariable and multivariable Cox proportional hazards models. RESULTS: At 3 years, OS was 69.6%, 77.1%, and 63.7% for patients treated with EBRT (n = 27 954), EBRT + BT (n = 209), or BT alone (n = 154), respectively (P = .01). On multivariable analysis, the instantaneous hazard of death for patients receiving EBRT + BT was 25% (Hazard ratio [HR] = 0.75, 95% CI: 0.58-0.98) lower than patients receiving only EBRT (P = .03). CONCLUSIONS: The addition of BT to EBRT in BOT cancer has an OS benefit.
BACKGROUND: We performed an analysis of the National Cancer Database (NCDB) to evaluate overall survival (OS) in patients with base of tongue (BOT) cancer treated with external beam radiation therapy (EBRT) combined with brachytherapy (BT). METHODS: The tongue NCDB Participant User File was used to obtain demographic and clinical patient data. The Kaplan-Meier method was used to determine OS. Significance was determined using univariable and multivariable Cox proportional hazards models. RESULTS: At 3 years, OS was 69.6%, 77.1%, and 63.7% for patients treated with EBRT (n = 27 954), EBRT + BT (n = 209), or BT alone (n = 154), respectively (P = .01). On multivariable analysis, the instantaneous hazard of death for patients receiving EBRT + BT was 25% (Hazard ratio [HR] = 0.75, 95% CI: 0.58-0.98) lower than patients receiving only EBRT (P = .03). CONCLUSIONS: The addition of BT to EBRT in BOT cancer has an OS benefit.
Authors: Leonid B Reshko; Jeremy T Gaskins; Jeffrey M Bumpous; Paul A Tennant; Zafrulla Khan; Keith Sowards; Craig L Silverman; Neal E Dunlap Journal: Contemp Oncol (Pozn) Date: 2021-11-24